# LATITUDE Trial: Cabenuva Superior Efficacy

**ID:** TRT-010
**Year:** 2024
**Source:** ViiV
**Link:** [https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2024/march/interim-data-at-croi-indicating-superior-efficacy/](https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2024/march/interim-data-at-croi-indicating-superior-efficacy/)

---

## Abstract

Phase 3 interim data showing Cabenuva superior to daily oral therapy in patients with adherence challenges.

---

## Key Concepts

- Primary research focus from 2023-2025 HIV literature
- Relevant to understanding HIV biology, treatment, or prevention
- Contributes to the broader HIV research landscape

---

## Relevance to Project

This paper contributes to the Ternary VAE bioinformatics project by providing context on:
- HIV sequence evolution and variability
- Biological constraints on viral fitness
- Therapeutic targets and resistance mechanisms

---

*Added: 2025-12-24*
